Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.58 |
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747463 | 0.91 | KDR (0.57) | KDRBRAFMETSIRT2SIRT1 | |
| SCHEMBL4548755 | 0.91 | KDR (0.58) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2747087 | 0.91 | SIRT2 (0.62) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2746237 | 0.91 | KDR (0.60) | KDRBRAFMETSIRT2SIRT1 | |
| SCHEMBL2748670 | 0.91 | KDR (0.62) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2749251 | 0.90 | KDR (0.70) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2747536 | 0.90 | KDR (0.58) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL4548758 | 0.90 | KDR (0.59) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2746821 | 0.90 | RAF1 (0.61) | KDRBRAFSIRT2SIRT1SIRT3 | |
| SCHEMBL2747846 | 0.90 | KDR (0.57) | KDRBRAFSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885BRAF 170/4885MET 3/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885BRAF 170/4885MET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.